Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFx-Hu2.0 + Pembrolizumab in Advanced Merkel Cell Carcinoma
NCT06940440Phase 1Recruiting
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IFx-Hu2.0 in Merkel cell carcinoma (MCC), sponsored by TuHURA Biosciences, Inc. Primary endpoints: Safety at 28 days and Feasibility at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
IFx-Hu2.0
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06940440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940440.